Myriad RBM to Perform Protein Biomarker Discovery on Over 8,000 Serum Samples From Patients With Pre-Diabetes or Type 2 Diabetes

SALT LAKE CITY, Dec. 10, 2012 (GLOBE NEWSWIRE) — Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, andPopulation Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBMwill perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the world’s longest and largest randomized clinical trial in pre- and early diabetes. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI.